Edesa Biotech, Inc. (NASDAQ: EDSA) has released its quarterly report for the period ending March 31, 2025, revealing both strides and challenges in its operations and financial health.
Key Highlights:
Revenue from reimbursement grant income totaled $353,463 for the six months ended March 31, 202...